Memo

To: User of Circular of Information

From: Christine Driscoll, Director, Regulatory Affairs and Donna Strauss, Executive Director, Core Operations

Date: June 3, 2020

Re: Circular of Information Update

In accordance with Food and Drug Administration (FDA) Guidance for Industry: Revised Recommendations to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Components, April 2020, New York Blood Center is providing an update to the Creutzfeldt-Jakob disease language.

The following warning statement is being provided for whole blood and blood components intended for transfusion and is to be considered a part of the Circular of Information.

Because Whole blood and blood components are made from human blood, they may carry a risk of transmitting infectious agents (e.g., viruses, bacteria, parasites, the variant Creutzfeldt-Jakob disease (vCJD) agent, and theoretically, the Creutzfeldt-Jakob disease agent (CJD)).